First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
Wei M, Zhao R, Cao Y, Wei Y, Li M, Dong Z, Liu Y, Ruan H, Li Y, Cao S, Tang Z, Zhou Y, Song W, Wang Y, Wang J, Yang G, Yang C.
Wei M, et al.
Eur J Med Chem. 2021 Jan 1;209:112903. doi: 10.1016/j.ejmech.2020.112903. Epub 2020 Oct 9.
Eur J Med Chem. 2021.
PMID: 33256948